Autoimmune Discovery Panel
Helping Your Research
The nCounter Autoimmune Discovery Panel is designed to enable researchers to discover links between known autoimmune disease associated germline variants and gene expression. The genes were selected in collaboration with leading autoimmune researchers and are linked to the top nine autoimmune diseases. This panel is made-to-order and you can add on up to 55 gene targets to the panel with the Panel Plus product to customize the panel to your research project.
How it Works
The Human nCounter Autoimmune Discovery Panel is a 770-gene panel that provides analysis of the links between known disease associated mutations and gene expression changes, allowing researchers to identify new gene functions and to look at gene expression in response to treatment. Highlights of the Autoimmune Discovery Panel include:
Discovery tool for disease-associated mutation gene function studies and biomarker characterization
Comprehensive content associated with nine autoimmune diseases
Gene expression profiling of immune response together with gene mutations
Made-to-order & customizable with the Panel Plus option – add up to 55 user-defined genes
Simple workflow, user-friendly, and efficient with just 15 minutes total hands-on time
Panel Selection Tool
Find the gene expression panel for your research with easy to use panel proFind Your Panel
Coverage of Autoimmune Diseases
Disease-specific annotations for nine autoimmune disease types and human immune response genes were assigned across all genes in the autoimmune discovery panel, allowing for the identification of gene functions and signatures for all autoimmune diseases.
Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.
PURPOSE: Patients with heterozygous gain-of-function (GOF) mutations in STAT1 frequently exhibit chronic mucocutaneous candidiasis (CMC), immunodeficiency and autoimmune manifestations. Several treatment options including targeted therapies and hematopoietic stem cell transplantation (HSCT) are available for STAT1 GOF patients but modalities and outcomes are not well established.
The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus.
Objectives: Type I interferons (IFNs) play an important role in the pathophysiology of systemic lupus erythematosus (SLE). While cross-sectional data suggest an association between IFN-induced gene expression and SLE disease activity, interest in this as a biomarker of flare has been tempered by a lack of fluctuation with disease activity in the majority of patients.
The Role of Brain-Derived Neurotrophic Factor in Irritable Bowel Syndrome.
Several studies have implied a role of brain-derived neurotrophic factor (BDNF) in abdominal pain modulation in irritable bowel syndrome (IBS). The aim of this study was to establish BDNF protein expression in human colonic biopsies and to show variation in IBS compared to controls.